Late-Breaking Clinical Trials III: Interventional Cardiology
Monday, March 15, 10:30 AM - 12:00 PM
Each year at the ACC meeting, program planners pour through abstracts to include in the late-breaking clinical trials sessions. This year, they picked 30 abstracts out of more than 100 that were submitted. Many of the late-breaking selections promise to be game-changers. If you want to get a sense of what your future practice might look like, you need to sit in on this session.
Much data already exist on drug-eluting stents (DES) and more mature data are emerging each year. Interventionalists know that DES have a place in their practice, but they want to know more, such as will DES perform as good in everyday practice as they did in highly controlled trials. We might get that answer in this session regarding zotarolimus- and sirolimus-eluting stents.
To address the problem of stent thrombosis and deliverability, researchers have been testing various permutations of DES, such as polymer-free stents and stents with thinner struts. We will see the results of such trials in this session.
Also, can triple-antiplatelet therapy be in the near future? That will depend on the results of the CILON-T study, which will be revealed in this session, even as questions still remain about the optimal duration of dual-antiplatelet therapy. The last abstract, however, will address optimal dual-antiplatelet therapy.
Medicine is increasingly moving toward individualized care. It might turn out that triple-antiplatelet therapy has a place within a certain patient population. Studies such as this, depending on the results, if they don't overhaul existing protocols, they can at least give interventionalists more options to better treat their patients.
To help attendees better understand these late-breaking trials, there will be a vigorous debate by a panel of distinguished experts following each presentation.
The abstracts are:
Location: Murphy Ballroom
Panelists:
George D. Dangas, MD, New York
Robert A. Harrington, MD, Durham, N.C.
Laura Mauri, MD, Boston
Franz-Josef Neumann, MD, Munich, Germany
Each year at the ACC meeting, program planners pour through abstracts to include in the late-breaking clinical trials sessions. This year, they picked 30 abstracts out of more than 100 that were submitted. Many of the late-breaking selections promise to be game-changers. If you want to get a sense of what your future practice might look like, you need to sit in on this session.
Much data already exist on drug-eluting stents (DES) and more mature data are emerging each year. Interventionalists know that DES have a place in their practice, but they want to know more, such as will DES perform as good in everyday practice as they did in highly controlled trials. We might get that answer in this session regarding zotarolimus- and sirolimus-eluting stents.
To address the problem of stent thrombosis and deliverability, researchers have been testing various permutations of DES, such as polymer-free stents and stents with thinner struts. We will see the results of such trials in this session.
Also, can triple-antiplatelet therapy be in the near future? That will depend on the results of the CILON-T study, which will be revealed in this session, even as questions still remain about the optimal duration of dual-antiplatelet therapy. The last abstract, however, will address optimal dual-antiplatelet therapy.
Medicine is increasingly moving toward individualized care. It might turn out that triple-antiplatelet therapy has a place within a certain patient population. Studies such as this, depending on the results, if they don't overhaul existing protocols, they can at least give interventionalists more options to better treat their patients.
To help attendees better understand these late-breaking trials, there will be a vigorous debate by a panel of distinguished experts following each presentation.
The abstracts are:
- Randomized All-Comer Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Coronary Stents: 18-Month Follow-up in the SORT OUT III Trial
- Randomized Trial of a Polymer-Free Dual Drug-Eluting Stent versus Polymer-Based Cypher and Endeavor Drug-Eluting Stents: Two-Year Clinical and Angiographic Outcomes
- First Report of the PERSEUS Randomized Controlled Trial Comparison of a Novel Platinum-Chromium, Thin-Strut TAXUS Element Stent Versus the TAXUS Express Stent in de novo Coronary Stenoses
- Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications after Drug-eluting Stent Implantation for Coronary Heart Disease: Influence of Cilostazol-Based Triple Anti-platelet Therapy on Ischemic Complication after Drug-Eluting Stent Implantation (CILON-T) Study
- Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents Implantation: A Randomized, Multi-center Trial
Location: Murphy Ballroom
Panelists:
George D. Dangas, MD, New York
Robert A. Harrington, MD, Durham, N.C.
Laura Mauri, MD, Boston
Franz-Josef Neumann, MD, Munich, Germany